Bahman Akbari

Dr. Bahman Akbari

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in International Reviews of Immunology
Verified
Journal Article
Closed access
BABahman Akbari
Bahman Akbari
SFSafar Farajnia
Safar Farajnia
SKShiva Ahdi Khosroshahi
Shiva Ahdi Khosroshahi
FSFatemeh Safari
Fatemeh Safari
MYMohammadreza Yousefi
Mohammadreza Yousefi
LRLeila Rahbarnia
Leila Rahbarnia
Immunotoxins are a novel class of cancer therapeutics that contains a cytotoxic agent fused to a targeting moiety. Various toxic agents from different sources are used in immunotoxin development, including bacterial, plant and human origin cytotoxic elements. Although bacterial and plant-derived toxins are highly toxic and commonly used in immunotoxins, their immunogenicity for human restricted their application in cancer therapy. Here, we discuss the advantages and limitations of bacterial toxins such as Pseudomonas and Diphtheria toxins, plant toxins such as ricin and gelonin, and some endogenous protein of human origin such as RNases and Granzymes. This article will also review different generations of immunotoxins with special focus on immunotoxins which are under clinical trials or approved for clinical use. Finally, current deimmunization strategies for development of new less-immunogenic recombinant immunotoxins will be discussed. Abbreviations: mAbs: Monoclonal antibodies; EF2: elongation factor 2; ITs: Immunotoxins; DT: Diphtheria toxin; PE: Pseudomonas exotoxin; dgA: de-glycosylated A-chain of ricin; rGel: recombinant de-glycosylated form of gelonin; NKC: natural killer cells; HTR: human transferrin receptor; EGF: epidermal growth factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; DAB389: truncated Diphtheria toxin; B-CCL: B-cell chronic lymphocytic leukemia; RCC: renal cell carcinoma; GVHD: Graft-versus-host disease; EGFR: epidermal growth factor receptor; AML: acute myeloid leukemia; Fab: fragment antigen-binding; dsFv: disulfide-stabilized fragment variable; scFv: single-chain fragment variable; B-ALL: B-lineage Acute Lymphoblastic Leukemia; Fv: fragment variable; HCL: hairy cell leukemia; IL-2R: Interleukin-2 receptor; CR: complete response; CLL: chronic lymphocytic leukemia; ATL: adult T-cell leukemia; DARPins: designed Ankyrin repeat proteins; pmol: picomolar; HAMA: human-anti mouse antibody

2 December 2019 in Critical Reviews in Biotechnology
Verified
Journal Article
Closed access
FSFatemeh Safari
Fatemeh Safari
MSMehrdad Sharifi
Mehrdad Sharifi
SFSafar Farajnia
Safar Farajnia
BABahman Akbari
Bahman Akbari
MAMohammad Karimi Baba Ahmadi
Mohammad Karimi Baba Ahmadi
YGYounes Ghasemi
Younes Ghasemi
Since the dawn of life, bacteria and phages are locked in a constant battle and both are perpetually changing their tactics to overcome each other. Bacteria use various strategies to overcome the invading phages, including adsorption inhibition, restriction–modification (R/E) systems, CRISPR–Cas (clustered regularly interspaced short palindromic repeats–CRISPR-associated proteins) systems, abortive infection (Abi), etc. To counteract, phages employ intelligent tactics for the nullification of bacterial defense systems, such as accessing host receptors, evading R/E systems, and anti-CRISPR proteins. Intense knowledge about the details of these defense pathways is the basis for their broad utilities in various fields of research from microbiology to biotechnology. Hence, in this review, we discuss some strategies used by bacteria to inhibit phage infections as well as phage tactics to circumvent bacterial defense systems. In addition, the application of these strategies will be described as a lesson learned from bacteria and phage combats. The ecological factors that affect the evolution of bacterial immune systems is the other issue represented in this review.

21 November 2016 in Journal of Drug Targeting
Verified
Journal Article
Closed access
LRLeila Rahbarnia
Leila Rahbarnia
SFSafar Farajnia
Safar Farajnia
HBHossein Babaei
Hossein Babaei
JMJafar Majidi
Jafar Majidi
KVKamal Veisi
Kamal Veisi
BABahman Akbari
Bahman Akbari
Phage display technology as a selection-based system is an attractive method for evolution of new biological drugs. Unique ability of phage libraries for displaying proteins on bacteriophage surfaces enable them to make a major contribution in diverse fields of researches related to the diagnosis and therapy of diseases. One of the great challenges facing researchers is the modification of phage display technology and the development of new applications. This article reviews the molecular basis of phage display library, and summarizes the novel and specific applications of this technique in the field of biological drugs development including therapeutic antibodies, peptides, vaccines, and catalytic antibodies.

30 November 2012 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
NMNejat Mahdieh
Nejat Mahdieh
ASAtefeh Shirkavand
Atefeh Shirkavand
BRBahareh Rabbani
Bahareh Rabbani
MTMustafa Tekin
Mustafa Tekin
BABahman Akbari
Bahman Akbari
SZSirous Zeinali
Sirous Zeinali

3 December 2020 in Journal of Drug Targeting
Verified
Journal Article
Closed access
JSJafar Sharifi
Jafar Sharifi
MKMohammad Reza Khirehgesh
Mohammad Reza Khirehgesh
FSFatemeh Safari
Fatemeh Safari
BABahman Akbari
Bahman Akbari
Targeted therapy is one of the favorable methods used in cancer treatment. Several recombinant proteins and small-molecules such as monoclonal antibodies, antibody fragments, and peptides are used to this aim. Nanobody is a camelid antibody fragment that is very effective in targeted therapy. Recently, several anti- EGFR (epidermal growth factor receptor) nanobodies have been developed and utilized for diagnosis and therapy of EGFR overexpressing tumors. Anti- EGFR nanobodies used in drug delivery systems, photodynamic therapy (PDT) and/or conjugated to other molecules such as quantum dots (QDs), nanoparticles, liposome, tumor penetration peptides, neural stem cells (NSC), and chimeric antigen receptor T cells (CART cells). In this review, we discuss the structure and function of EGFR and nanobody, the current status of EGFR targeting, and recent developments in anti- EGFR nanobodies. To gain sound insight into the issue at hand, we focus on the most powerful anti- EGFR nanobodies.

8 March 2021 in Journal of Drug Targeting
Verified
Journal Article
Closed access
MKMohammad Reza Khirehgesh
Mohammad Reza Khirehgesh
JSJafar Sharifi
Jafar Sharifi
FSFatemeh Safari
Fatemeh Safari
BABahman Akbari
Bahman Akbari
Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively. ITs have been successful in haematologic malignancies treatment. However, ITs penetrate poorly into solid tumours because of their large size. Use of camelid antibody fragments known as nanobodies (Nbs) as a targeting moiety may overcome this problem. Nbs are the smallest fragment of antibodies with excellent tumour tissue penetration. The ability to recognise cryptic (immuno-evasive) target antigens, low immunogenicity, and high-affinity are other fundamental characteristics of Nbs that make them suitable candidates in targeted therapy. Here, we reviewed and discussed the structure and function of ITs, Nbs, and nanobody-based ITs. To gain sound insight into the issue at hand, we focussed on nanobody-based ITs.